A recent Nordic research study has shed light on the potential increased risk of stillbirth among pregnant women infected with COVID-19. This comprehensive study, the largest of its kind, analysed data from 389,949 births across Norway, Sweden and Denmark. The findings revealed a 2.4 times higher risk of stillbirth among women who contracted COVID-19 during pregnancy.
While stillbirth remains a rare occurrence, the study found that the absolute risk was 2.3 per 100,000 follow-up days for pregnant women without COVID-19. In contrast, the risk was 5.8 per 100,000 follow-up days for those who contracted the virus during pregnancy. Notably, the risk of stillbirth was highest within the first two weeks of infection.
The study also discovered that the risk of stillbirth varied based on the COVID-19 variant that the pregnant woman tested positive for. The risk was highest during the period when the Delta variant was dominant. However, due to changes in COVID-19 testing recommendations, the risk associated with current variants remains unknown.
In light of these findings, the Norwegian Institute of Public Health recommends pregnant women get vaccinated against COVID-19 during their second or third trimester. This recommendation is based on research showing a certain increased risk of serious illness or complications among pregnant women infected by COVID-19, with no connected risk for the mother, child, or pregnancy among those vaccinated.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
